SCOTUS – IP Law Watch

U.S. Supreme Court Vacates Dog Toy Company’s Win in Jack Daniel’s Parody Trademark Dispute

Jun 09 2023

A unanimous U.S. Supreme Court held on June 8, 2023, that a dog toy company’s “parody” chew toy that mimics Jack Daniel’s widely recognized whiskey bottle does not escape trademark liability merely because the toy has “expressive content” or because it parodies Jack Daniel’s. Justice Kagan delivered the narrow opinion, writing that because the dog toy company, VIP Products LLC (“VIP”), used Jack Daniel’s trademarks as a designation of source for VIP’s own goods – i.e. using another’s trademark as a trademark – there is no special threshold First Amendment inquiry. The Supreme Court vacated the prior Ninth Circuit opinion that VIP’s use was protected under the First Amendment and the so-called Rogers test for “expressive” works, and remanded for consideration of whether VIP’s use is likely to cause consumer confusion. The Supreme Court expressly did not evaluate whether or how the well-known Rogers test may or may not apply in other contexts. Jack Daniel’s Properties, Inc. v. VIP Products LLC, 599 U.S. ___ (2023).

Copyright Dispute Over Andy Warhol’s Portraits of Prince Heading to U.S. Supreme Court

Mar 30 2022

The U.S. Supreme Court will review the standard for a “transformative” work as “fair use” under the Copyright Act. Specifically, whether a second work of art is “transformative” when it conveys a different meaning or message from its source material, or not where it recognizably derives from and retains the essential elements of its source material.

The Court agreed to review the Second Circuit’s decision that Andy Warhol’s Prince Series portraits of the musician Prince did not make fair use of celebrity photographer Lynn Goldsmith’s photograph of Prince. Andy Warhol Found. for the Visual Arts, Inc. v. Goldsmith, No. 21-869 (petition granted Mar. 28, 2022).

Sandoz v. Amgen—Biosimilars at the Supreme Court—Oral Argument

May 02 2017

All nine U.S. Supreme Court justices heard argument on Wednesday April 26th, in Sandoz Inc., v. Amgen Inc. The Supreme Court is reviewing interpretations of the Biologics Price Competition and Innovation Act (BPCIA) made by the U.S. Court of Appeals for the Federal Circuit. Wednesday’s arguments focused on four main issues:

whether the FDA could preliminarily grant licensure prior to the expiration of the 12 year statutory period;
whether the notice of commercial marketing requires official licensure to be made;
whether the “patent dance” was required by the BPCIA; and
whether state law could be used to enforce compliance with the “patent dance” elements of the BPCIA.

Industry watchers hope that the Supreme Court will streamline the process for getting biosimilars to market by providing increased certainty.

To read the full alert, click here.

By: Theodore J. Angelis, Peter Giunta, Kenneth C. Liao, Margaux L. Nair and Jenna Bruce

Tag:SCOTUS